Pembrolizumab Plus Pemetrexed, Carboplatin Prolongs Survival in NSCLC

Share this content:
Initial analysis of cohort G of KEYNOTE-021 at a median of 10.6 months showed that pembrolizumab significantly improved overall response rate and progression-free survival compared with pemetrexed/car
Initial analysis of cohort G of KEYNOTE-021 at a median of 10.6 months showed that pembrolizumab significantly improved overall response rate and progression-free survival compared with pemetrexed/car
The following article features coverage from the IASLC 18th World Conference on Lung Cancer (WCLC) in Yokohama, Japan. Click here to read more of Cancer Therapy Advisor's conference coverage.

Evidence is building that overall survival (OS) among patients with advanced non-squamous non–small cell lung cancer (NSCLC) is prolonged by pembrolizumab plus pemetrexed and carboplatin compared with pemetrexed and carboplatin alone, according to a study presented at the International Association for the Study of Lung Cancer (IASLC) 18th Annual World Conference on Lung Cancer (WCLC) in Japan.1

In the phase 1/2 KEYNOTE-021 study (ClinicalTrials.gov Identifier: NCT02039674), researchers randomly assigned 123 patients with NSCLC to receive pemetrexed and carboplatin with or without pembrolizumab as first-line therapy. Initial analysis of cohort G at a median of 10.6 months showed that pembrolizumab significantly improved overall response rate (ORR) and progression-free survival (PFS).

The median follow-up was 18.7 months for this analysis. Patients who received pembrolizumab plus pemetrexed and carboplatin had an ORR of 57% vs 32% among patients who did not receive pembrolizumab (estimated difference 25%; 95% CI, 7%-41%; P = .0029). PFS was significantly prolonged for patients who received pembrolizumab, with a median of 19.0 months (95% CI, 8.5-not reached [NR]), vs 8.9 months (95% CI, 6.2-11.8) for patients who received pemetrexed and carboplatin alone (HR, 0.54; 95% CI, 0.33-0.88; P = .0067).

Patients who received pembrolizumab plus pemetrexed and carboplatin did not reach a median OS (95% CI, 22.8-NR) compared with 20.9 months (95% CI, 14.9-NR) among patients who received pemetrexed and carboplatin alone (HR, 0.59; 95% CI, 0.34-1.05; P = .0344).

Grade 3 to 5 adverse events were reported by 41% of patients who received pembrolizumab compared with 29% who received pemetrexed and carboplatin alone.

Read more of Cancer Therapy Advisor's coverage of the IASLC 18th World Conference on Lung Cancer (WCLC) by visiting the conference page.

Reference

  1. Borghaei H, Langer CJ, Gadgeel SM, et al. Pemetrexed-carboplatin plus pembrolizumab as first-line therapy for advanced nonsquamous NSCLC: KEYNOTE-021 cohort G update. Presented at: International Association for the Study of Lung Cancer 18th World Conference on Lung Cancer; October 2017; Yokohama, Japan. Abstract OA 17.01.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs